<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04828265</url>
  </required_header>
  <id_info>
    <org_study_id>282-HV-105</org_study_id>
    <nct_id>NCT04828265</nct_id>
  </id_info>
  <brief_title>Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects</brief_title>
  <official_title>A Phase 1, Open-Label Study to Assess the Safety, Tolerability, and Pharmacokinetics of Aldafermin in Healthy Adult Male Japanese and Non-Japanese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NGM Biopharmaceuticals, Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NGM Biopharmaceuticals, Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study to assess safety, tolerability, and pharmacokinetics of&#xD;
      Aldafermin (NGM282) in healthy adult male Japanese and non-Japanese subjects&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) of a single dose aldafermin</measure>
    <time_frame>4 days</time_frame>
    <description>Maximum observed plasma concentration (Cmax) of aldafermin (Day 1 through Day 4)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve of a single dose aldafermin</measure>
    <time_frame>4 days</time_frame>
    <description>Area under the concentration-time curve from time zero extrapolated to infinity (AUC infinity)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to maximum concentration (Tmax) of a single dose aldafermin</measure>
    <time_frame>4 days</time_frame>
    <description>Time to maximum concentration (Tmax)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent terminal elimination half-life (T1/2) of a single dose aldafermin</measure>
    <time_frame>4 days</time_frame>
    <description>Apparent terminal elimination half-life (T1/2)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Frequency of adverse events</measure>
    <time_frame>10 days</time_frame>
    <description>Frequency of treatment-emergency adverse events (TEAE) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Type of adverse events</measure>
    <time_frame>10 days</time_frame>
    <description>Severity and duration of treatment-emergency adverse events (TEAE) and serious adverse events (SAEs)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute change in concentration of biomarker 7-alpha-hydroxy-4-cholesten-3-one (C4)</measure>
    <time_frame>6 and 24 hours post dose</time_frame>
    <description>Absolute change from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change of C4</measure>
    <time_frame>6 and 24 hours post dose</time_frame>
    <description>Percent change from baseline</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Healthy Male</condition>
  <arm_group>
    <arm_group_label>Aldafermin 0.3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of a single dose of aldafermin 0.3mg in healthy adult male Japanese or non-Japanese subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aldafermin 1mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of a single dose of aldafermin 1mg in healthy adult male Japanese or non-Japanese subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aldafermin 3mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subcutaneous injection of a single dose of aldafermin 3mg in healthy adult male Japanese or non-Japanese subjects</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Aldafermin</intervention_name>
    <description>Single dose of aldafermin</description>
    <arm_group_label>Aldafermin 0.3mg</arm_group_label>
    <arm_group_label>Aldafermin 1mg</arm_group_label>
    <arm_group_label>Aldafermin 3mg</arm_group_label>
    <other_name>NGM282</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Male subjects between 18 and 65 years, inclusive, of age who are able to comprehend&#xD;
             and willing to sign an informed consent form (ICF).&#xD;
&#xD;
          2. Body mass index (BMI) range 18-35 kg/m2 (inclusive) at screening.&#xD;
&#xD;
          3. Healthy subjects with no clinically significant medical history or findings on&#xD;
             screening evaluation.&#xD;
&#xD;
          4. Clinical laboratory evaluations (e.g., fasted chemistry, complete blood count,&#xD;
             urinalysis) within the reference range for the test laboratory at screening, unless&#xD;
             deemed not clinically significant by the investigator.&#xD;
&#xD;
          5. Subjects with a female partner of childbearing potential must agree to consistent and&#xD;
             adequate birth control.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Clinically significant cardiovascular or cerebrovascular event or new diagnosis within&#xD;
             6 months of screening.&#xD;
&#xD;
          2. Clinically significant medical history or clinical manifestation of any significant&#xD;
             metabolic, allergic, hepatic, renal, hematological, pulmonary, gastrointestinal (GI),&#xD;
             neurological, or psychiatric disorder (as determined by the investigator).&#xD;
&#xD;
          3. History of malignancy, except resected, localized basal cell carcinoma, and squamous&#xD;
             cell carcinoma.&#xD;
&#xD;
          4. Abnormal, clinically significant electrocardiogram findings, in the opinion of the&#xD;
             investigator.&#xD;
&#xD;
          5. Abnormal, clinically significant liver function laboratory test results at screening&#xD;
             as determined by the investigator.&#xD;
&#xD;
          6. Calculated creatinine clearance (Cockcroft-Gault) &lt; 90 mL/min at screening.&#xD;
&#xD;
          7. Positive for hepatitis B surface antigen (HbsAg), human immunodeficiency antibodies&#xD;
             (antiHIV), or hepatitis C virus antibodies (antiHCV) plus HCV-RNA. Subjects who are&#xD;
             antiHCV positive, but HCV-RNA negative (secondary to treatment or viral clearance) are&#xD;
             eligible with at least a 1-year period since documented sustained viral response at&#xD;
             Week 12 post-treatment.&#xD;
&#xD;
          8. Participation in any other investigational study drug trial in which receipt of an&#xD;
             investigational study drug occurred within 5 half-lives or 30 days, whichever is&#xD;
             longer, prior to study entry.&#xD;
&#xD;
          9. Any acute or chronic condition that, in the opinion of the investigator, would limit&#xD;
             the subject's ability to complete and/or participate in this clinical study.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NGM Study Director</last_name>
    <role>Study Director</role>
    <affiliation>NGM Biopharmaceuticals, Inc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>NGM Study Director</last_name>
    <phone>(650) 243-5555</phone>
    <email>ngm282@ngmbio.com</email>
  </overall_contact>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 26, 2021</study_first_submitted>
  <study_first_submitted_qc>March 31, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2021</study_first_posted>
  <last_update_submitted>March 31, 2021</last_update_submitted>
  <last_update_submitted_qc>March 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

